We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
West Pharmaceutical sees strong growth from biologics, HVPs and higher-value containment solutions.
Annex 1 upgrades include nearly 800 active projects and could add about 200 basis points of revenue growth.
West Vantage and commodity inflation remain near-term challenges, while pricing helps offset higher costs.
West Pharmaceutical Services, Inc. (WST - Free Report) is well positioned for growth, backed by strong demand for HVPs, expanding biologics exposure and regulatory-driven Annex 1 conversions. However, tariff impacts and weak West Vantage results, which were hurt by a cyber incident, remain concerning.
Shares of this Zacks Rank #2 (Buy) company have gained 33.1% year to date compared with the industry's 3.7% growth. The S&P 500 Index has risen 10% in the same time frame.
West Pharmaceutical, with a market capitalization of $25.48 billion, is a leading global manufacturer engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 16% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 17.4%.
Image Source: Zacks Investment Research
Positive Factors Driving WST’s Prospects
Strong Biologics Exposure Supports Higher-Value Growth:West Pharma’s biologics franchise provides an attractive structural growth opportunity because newer biologic medicines increasingly require sophisticated primary-containment solutions. Management noted that approximately 75% of new drug approvals in 2025 were large molecules, and West Pharma continues to achieve more than 90% win rates for these new molecules.
Products such as NovaPure and FluroTec are particularly well positioned because they address advanced containment requirements and carry higher ASPs and margins. The growing number of biologic launches, geographic expansions and indication additions could support West Pharma’s growth through new customer wins and greater utilization of its existing products.
Annex 1 Upgrades Provide a Multi-Year Revenue and Margin Opportunity:West Pharma is benefiting from a growing customer transition toward higher-value containment solutions, driven by Annex 1 sterility and contamination-control requirements. Management disclosed nearly 800 active projects, up 50% from the previous year’s level, while describing the opportunity as still in its early stages.
The company expects Annex 1 and related upgrades to contribute about 200 basis points of revenue growth in 2026, with potential upside beyond that level. Because customers can retain existing formulations while adding services such as pharmaceutical washing and Envision inspection, West Pharma can increase average selling prices and margins without requiring equivalent increases in component volumes.
Moreover, Standard Products portfolio represents an important strategic funnel for future HVP conversion. West Pharma can transition customers from standard components to higher-value HVP products when pharmaceutical manufacturers seek more advanced containment, inspection or finishing capabilities.
Delivery Devices Show Stronger Underlying Momentum:HVP Delivery Devices delivered 29% organic growth in the second quarter, supported by strong performance across the portfolio. Although SmartDose 3.5 benefited from customer orders ahead of its July 1 transaction, management emphasized that the remaining portfolio, which includes SelfDose and Crystal Zenith, is also performing well.
SelfDose is seeing expansion across multiple customers and drug molecules, while Crystal Zenith targets high-value biologics, including cell and gene therapies. Management expects the core delivery-device portfolio to continue growing in the third and fourth quarters. This indicates that the segment’s improvement is not solely dependent on SmartDose-related timing and provides another avenue for West Pharma to participate in complex injectable-drug development.
Key Challenges Facing WST
West Vantage Remains a Near-Term Drag on Growth: West Vantage remains the weakest-performing major segment, with second-quarter organic revenue growth of only 0.8% versus 15.5% growth for the Proprietary Products segment. Management attributed the shortfall partly to the cyber incident, estimating a mid-single-digit impact on segment growth and pushing some revenues into the second half.
The pressure is likely to persist in the third quarter because the quarter represents the first period following the exit of a CGM contract. Management expects West Vantage revenues to reach a trough in the third quarter before improving in the fourth quarter as drug-handling operations increase. This creates near-term volatility and makes the company increasingly dependent on Proprietary Products to sustain consolidated growth.
Commodity Inflation Could Pressure Margin Expansion: West Pharma is facing higher costs from oil and commodity prices, creating a potential headwind for the company’s margin trajectory. Management said it is working to offset inflation through pricing and other measures, with pricing contributing 4 percentage points to the second-quarter revenue growth, above its historical 2% to 3% range.
However, greater reliance on pricing has the potential to hurt customer acceptance and the company’s ability to continue capturing the value of its products. While management maintained its margin outlook and expects more than 200 basis points of operating-margin expansion in 2026, persistent input-cost inflation could limit the pace of improvement if pricing does not fully offset higher production costs.
West Pharmaceutical Services, Inc. Price and Consensus
WST has been witnessing a stable estimate revision for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 3.8% to $8.93 per share, implying a gain of 22.5% from the prior-year reported level. The consensus mark for revenues is pegged at $3.37 billion, indicating a 9.7% increase from the 2025 reported level.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Inspire Medical Systems (INSP - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Inspire Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 195.9%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Key Takeaways
West Pharmaceutical Services, Inc. (WST - Free Report) is well positioned for growth, backed by strong demand for HVPs, expanding biologics exposure and regulatory-driven Annex 1 conversions. However, tariff impacts and weak West Vantage results, which were hurt by a cyber incident, remain concerning.
Shares of this Zacks Rank #2 (Buy) company have gained 33.1% year to date compared with the industry's 3.7% growth. The S&P 500 Index has risen 10% in the same time frame.
West Pharmaceutical, with a market capitalization of $25.48 billion, is a leading global manufacturer engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 16% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 17.4%.
Image Source: Zacks Investment Research
Positive Factors Driving WST’s Prospects
Strong Biologics Exposure Supports Higher-Value Growth:West Pharma’s biologics franchise provides an attractive structural growth opportunity because newer biologic medicines increasingly require sophisticated primary-containment solutions. Management noted that approximately 75% of new drug approvals in 2025 were large molecules, and West Pharma continues to achieve more than 90% win rates for these new molecules.
Products such as NovaPure and FluroTec are particularly well positioned because they address advanced containment requirements and carry higher ASPs and margins. The growing number of biologic launches, geographic expansions and indication additions could support West Pharma’s growth through new customer wins and greater utilization of its existing products.
Annex 1 Upgrades Provide a Multi-Year Revenue and Margin Opportunity:West Pharma is benefiting from a growing customer transition toward higher-value containment solutions, driven by Annex 1 sterility and contamination-control requirements. Management disclosed nearly 800 active projects, up 50% from the previous year’s level, while describing the opportunity as still in its early stages.
The company expects Annex 1 and related upgrades to contribute about 200 basis points of revenue growth in 2026, with potential upside beyond that level. Because customers can retain existing formulations while adding services such as pharmaceutical washing and Envision inspection, West Pharma can increase average selling prices and margins without requiring equivalent increases in component volumes.
Moreover, Standard Products portfolio represents an important strategic funnel for future HVP conversion. West Pharma can transition customers from standard components to higher-value HVP products when pharmaceutical manufacturers seek more advanced containment, inspection or finishing capabilities.
Delivery Devices Show Stronger Underlying Momentum:HVP Delivery Devices delivered 29% organic growth in the second quarter, supported by strong performance across the portfolio. Although SmartDose 3.5 benefited from customer orders ahead of its July 1 transaction, management emphasized that the remaining portfolio, which includes SelfDose and Crystal Zenith, is also performing well.
SelfDose is seeing expansion across multiple customers and drug molecules, while Crystal Zenith targets high-value biologics, including cell and gene therapies. Management expects the core delivery-device portfolio to continue growing in the third and fourth quarters. This indicates that the segment’s improvement is not solely dependent on SmartDose-related timing and provides another avenue for West Pharma to participate in complex injectable-drug development.
Key Challenges Facing WST
West Vantage Remains a Near-Term Drag on Growth: West Vantage remains the weakest-performing major segment, with second-quarter organic revenue growth of only 0.8% versus 15.5% growth for the Proprietary Products segment. Management attributed the shortfall partly to the cyber incident, estimating a mid-single-digit impact on segment growth and pushing some revenues into the second half.
The pressure is likely to persist in the third quarter because the quarter represents the first period following the exit of a CGM contract. Management expects West Vantage revenues to reach a trough in the third quarter before improving in the fourth quarter as drug-handling operations increase. This creates near-term volatility and makes the company increasingly dependent on Proprietary Products to sustain consolidated growth.
Commodity Inflation Could Pressure Margin Expansion: West Pharma is facing higher costs from oil and commodity prices, creating a potential headwind for the company’s margin trajectory. Management said it is working to offset inflation through pricing and other measures, with pricing contributing 4 percentage points to the second-quarter revenue growth, above its historical 2% to 3% range.
However, greater reliance on pricing has the potential to hurt customer acceptance and the company’s ability to continue capturing the value of its products. While management maintained its margin outlook and expects more than 200 basis points of operating-margin expansion in 2026, persistent input-cost inflation could limit the pace of improvement if pricing does not fully offset higher production costs.
West Pharmaceutical Services, Inc. Price and Consensus
West Pharmaceutical Services, Inc. price-consensus-chart | West Pharmaceutical Services, Inc. Quote
Estimate Trend
WST has been witnessing a stable estimate revision for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 3.8% to $8.93 per share, implying a gain of 22.5% from the prior-year reported level. The consensus mark for revenues is pegged at $3.37 billion, indicating a 9.7% increase from the 2025 reported level.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Inspire Medical Systems (INSP - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Inspire Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 195.9%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.